A claim about lymphoedema or lipoedema usually arrives with a source attached: a guideline, a review, an NHS page, a charity leaflet. The source gives the claim authority, but different sources hold authority for different jobs. A guideline can tell you what a group of experts recommends within a defined scope. It cannot tell you how well a treatment works. A review can tell you what a set of studies found. It cannot tell you whether you have a condition.
Matching the claim to the right kind of source is one of the most useful habits in evidence reading. This article describes five source types, what each can answer, and what each leaves open, using the sources examined in Book 01 of the Field Guide.
Editorial note: this article is educational and has not been medically reviewed. It explains how sources are built and read. It does not diagnose, triage, prescribe or promise an outcome. New, rapidly changing or worrying swelling or skin changes, or fever or feeling unwell, need appropriate NHS or urgent-care advice, and breathing difficulty, chest pain or collapse needs emergency help.
Start with the job the source was built to do
Chapter 1 of the Field Guide separates five kinds of authority: description, consensus, guidance, validation and diagnosis. A clinical description names a pattern. A consensus records an expert synthesis. Guidance turns evidence and judgement into advice for a defined audience. Validation asks whether a measure performs for a stated purpose and population. Diagnosis is a qualified clinical conclusion reached through assessment. A source may be strong in one role and unsuitable for another, and most errors in reading come from asking a source to do a job it was never designed for.
1. Clinical guidelines
What they are: structured statements for a defined clinical setting and audience. The 2024 S2k guideline on lipoedema (Faerber and colleagues, Journal der Deutschen Dermatologischen Gesellschaft) combines a systematic search with structured consensus. NICE NG101 (early and locally advanced breast cancer) and NICE NG141 (cellulitis and erysipelas: antimicrobial prescribing) are UK guidelines with named scopes.
What they can answer: what a guideline group agrees or recommends within its scope, which terms it uses, and where it says evidence is lacking. The S2k guideline, for instance, frames lipoedema diagnosis as clinical and notes the absence of a laboratory biomarker.
What they cannot answer: they do not validate a test, give a personal decision or apply beyond their scope. NG101 concerns breast cancer, so it is not general lymphoedema guidance. NG141 concerns infection prescribing, so it is not a lymphoedema or lipoedema diagnostic guide. A guideline also does not supply an effect size by itself, because that comes from the studies underneath it. And detail is not diagnosis: a guideline does not become a diagnostic instrument by being thorough.
The S2k document shows that categories blur. It is both a guideline and a structured consensus. When a source straddles types, describe it by how it was actually made.
2. Consensus statements
What they are: expert syntheses of literature and practice. The International Society of Lymphology 2020 consensus (Lymphology) on peripheral lymphoedema is the example Book 01 uses throughout.
What they can answer: shared vocabulary, assessment principles, how a field organises management and where experts agree.
What they cannot answer: they are not experimental validation. They do not provide a universal diagnostic checklist, and a consensus on management as a package does not isolate the effect of any single element. Consensus can organise questions. It cannot stand in for the evidence that answers them.
3. Systematic reviews
What they are: structured searches and syntheses of the studies on a question, sometimes with a meta-analysis that pools results. Book 01 draws on several kinds:
- Cochrane reviews of randomised trials, such as Ezzo and colleagues on manual lymphatic drainage after breast-cancer treatment (six trials) and Stuiver and colleagues on preventing upper-limb lymphoedema.
- A review of measurement properties of lymphoedema instruments (Hidding and colleagues).
- A review of diagnostic imaging in lipoedema (van la Parra and colleagues), based on observational research.
- A quality-of-life meta-analysis in lipoedema (Günay and colleagues) and a meta-analysis of liposuction cohorts (Mortada and colleagues).
- A systematic review and meta-analysis of incidence of arm lymphoedema after breast cancer (DiSipio and colleagues).
What they can answer: what the gathered studies show, how consistent they are, where quality is limited and where evidence is missing.
What they cannot answer: a review is only as good as the studies it collects. The Mortada review draws mostly on observational cohorts and has no randomised comparison with conservative care, so its pooled estimate cannot repair inconsistent reporting underneath. The imaging review found heterogeneous methods and no standalone threshold. The quality-of-life review found mostly cross-sectional data and generic instruments. A systematic review does not make weak evidence strong, and calling something a systematic review does not tell you the question it answered or the population it covered.
4. Observational studies
What they are: studies that describe or compare people without assigning an intervention. They include cohort studies, cross-sectional studies, service-based studies and screening surveys. Examples in the source set are Moffatt and colleagues' study of chronic oedema in UK community nursing services (Lymphatic Research and Biology, 2019), Schook and colleagues' specialist cohort of 138 paediatric patients with primary lymphoedema (Plastic and Reconstructive Surgery, 2011) and Amato and colleagues' online screening sample in Brazil (Jornal Vascular Brasileiro, 2022).
What they can answer: who was in a defined group, what was observed in it and which features were associated.
What they cannot answer: observational designs do not establish that one thing caused another, and the group studied limits who the finding describes. A service caseload is not a population survey, a specialist paediatric cohort is not an age guide, and an online screening sample is not a clinical diagnosis. Before-and-after changes in selected cohorts may reflect selection, other care, or who stayed to be assessed.
Two further designs deserve a mention. Qualitative studies, such as the Welsh focus-group study of clinic attendees, describe what participants reported and do not measure how common it is. Measure development and validation studies, such as those for LYMQOL, Lymph-ICF and LYMPROM, test whether a questionnaire performs for a stated purpose, language and population. Neither type diagnoses.
5. NHS, NICE procedure, BLS and LSN pages
What they are: information and governance sources with practical jobs.
- NHS pages on lymphoedema and lipoedema give public orientation and signposting.
- NICE interventional procedure guidance (HTG618 for lipoedema and HTG622 for chronic lymphoedema, formerly IPG721 and IPG723) sets a named procedure's evidence and safety governance.
- British Lymphology Society materials give professional and operational context.
- Lymphoedema Support Network pages give patient information and signposting.
What they can answer: how a UK source explains terms in plain language, what a governing body says about a named procedure, how professionals describe service practice and where to look next.
What they cannot answer: they are not research cohorts, efficacy syntheses or validation studies, and a trusted name does not change that. An NHS page does not supply an effect estimate. Procedure guidance is not a care pathway or a personal suitability decision, and its scope belongs to its named procedure and condition. BLS and LSN materials are not automatically peer-reviewed efficacy evidence. None of them decides local eligibility, funding or waiting times. For the surgery guidance specifically, the earlier explainer on lipoedema surgery evidence covers it in depth, so it is not repeated here.
Common mismatches to watch for
- A guideline cited as though it were a test or a personal diagnosis.
- An information page cited to show how well something works.
- A pooled estimate from observational cohorts described as proof of cause.
- One service's caseload described as a national or whole-population figure.
- A breast-cancer guideline applied to every form of lymphoedema.
- A validation study for one questionnaire offered as validation of a diagnosis.
- A procedure-governance page read as a recommendation or a ban for an individual.
The mismatch is rarely about a source being bad. It comes from the source being asked a question outside its design.
A five-question routine
- What type of source is this, judged by how it was made and not by its label?
- Which question was it designed to answer?
- Who or what does it cover, and does that match the claim?
- What does the source itself say it cannot show?
- If the claim goes further than the answers to questions 2 to 4, what additional evidence would it need?
The same routine works for a web page, a social post or a leaflet: find the source behind the claim, then check it against these questions. The UK services context page compares peer-reviewed evidence with NHS, NICE, BLS and LSN sources side by side, and the glossary defines PROMs, PICO-S and GRADE.
What this evidence does not establish
Reading source types well improves a question. It does not produce a diagnosis, a prognosis, a referral route or a treatment choice, and no source type here replaces assessment by a qualified professional. The research index sets out the five evidence hubs these sources feed into.
Sources used
- International Society of Lymphology. 2020 Consensus Document. Lymphology. 2020;53(1):3-19. Expert consensus. DOI.
- Faerber G et al. S2k guideline lipedema. J Dtsch Dermatol Ges. 2024;22(9):1303-1315. Guideline and structured consensus. DOI.
- Ezzo J et al. Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database Syst Rev. 2015;Issue 5:CD003475. DOI.
- Stuiver MM et al. Conservative interventions for preventing clinically detectable upper-limb lymphoedema. Cochrane Database Syst Rev. 2015;Issue 2:CD009765. DOI.
- Hidding JT et al. Measurement properties of instruments for measuring of lymphedema. Phys Ther. 2016;96(12):1965-1981. DOI.
- van la Parra RFD et al. Diagnostic imaging in lipedema. Obesity Reviews. 2024;25(1):e13648. DOI.
- Günay UB et al. Health-related quality of life among lipedema patients. Phlebology. 2025. PubMed.
- Mortada H et al. Safety and effectiveness of liposuction modalities in managing lipedema. Arch Plast Surg. 2024;51(5):510-526. DOI.
- DiSipio T et al. Incidence of unilateral arm lymphoedema after breast cancer. Lancet Oncol. 2013;14(6):500-515. PubMed.
- Moffatt CJ et al. Prevalence and risk factors for chronic edema in UK community nursing services. Lymphat Res Biol. 2019;17(2):147-154. DOI.
- Schook CC et al. Primary lymphedema: clinical features and management in 138 pediatric patients. Plast Reconstr Surg. 2011;127(6):2419-2431. DOI.
- Amato ACM et al. Lipedema prevalence and risk factors in Brazil. J Vasc Bras. 2022;21:e20210198. Full text.
- NHS: Lymphoedema and Lipoedema. NICE: NG101, NG141, HTG618 and HTG622. British Lymphology Society and Lymphoedema Support Network.
